SCHEMBL6793810

SCHEMBL6793810

Cc1ccc(-c2ccccc2C(=O)Nc2ccc(CNC(=O)c3ccccn3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 3/20 0.52
▸ GRM4 Q14833 1/20 0.51
▸ KMT2A Q03164 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ HPGD P15428 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ CHRNB2 P17787 1/20 0.48
▸ CHRNB4 P30926 1/20 0.48
▸ CHRNA3 P32297 1/20 0.48
▸ CHRNA4 P43681 1/20 0.48
▸ DHODH Q02127 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799242 0.91 CHRNB2 (0.59) KDRGRM4KMT2ASMN1; SMN2HPGD
SCHEMBL6794304 0.91 GRM4 (0.55) KDRGRM4KMT2AHPGDHTT
SCHEMBL6796384 0.87 SMO (0.55) KDRGRM4
SCHEMBL6492242 0.84 GCGR (0.49) KDRGRM4
SCHEMBL18715392 0.83 SMN1; SMN2 (0.68) KMT2ASMN1; SMN2HPGDHTTKDM4E
SCHEMBL6788071 0.82 KDM4E (0.51) KDRKMT2ASMN1; SMN2HTTLMNA
SCHEMBL7517695 0.80 NPC1 (0.55) KMT2AHPGDKDM4ECHRNB2CHRNB4
SCHEMBL6792355 0.79 KMT2A (0.59) KMT2ASMN1; SMN2HTTLMNAKDM4E
SCHEMBL7606603 0.79 CES1 (0.55) KDRGRM4HDAC1
SCHEMBL6037590 0.78 KDR (0.78) KDRGRM4SMN1; SMN2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 — — US claimed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 — — US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 — — EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 KDR 3180/4885GRM4 4334/4885KMT2A 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback